Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma Pharmaceutical TechnologyThe FDA has issued a complete response letter to Replimune's biologics license application concerning the RP1 therapy.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story Post navigation Previous: FDA hands another rejection to Replimune’s melanoma therapyNext: Data backs GSK’s ovarian cancer blockbuster hopes Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
